20:22 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves cepiplimab from Sanofi, Regeneron

FDA approved Libtayo cemiplimab-rwlc from partners Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or...
22:19 , Sep 28, 2018 |  BC Extra  |  Company News

FDA approves cemiplimab from Sanofi, Regeneron

FDA approved Libtayo cemiplimab-rwlc from partners Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or...
21:40 , Sep 25, 2018 |  BC Extra  |  Company News

Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year. Cardiometabolic disorders...
17:24 , Sep 14, 2018 |  BC Week In Review  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
22:19 , Sep 13, 2018 |  BC Extra  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:33 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Principia seeks IPO ahead of Phase III trials for Btk program

Principia Biopharma Inc. (South San Francisco, Calif.) proposed late Aug. 17 to raise $86.3 million in an IPO on NASDAQ and revealed that it raised $49.7 million in a series C round this month. Underwriters...
20:21 , Aug 20, 2018 |  BC Extra  |  Financial News

With Btk program bound for Phase III, Principia seeks IPO

Principia Biopharma Inc. (South San Francisco, Calif.) proposed late Friday to raise $86.3 million in an IPO on NASDAQ and revealed that it raised $49.7 million in a series C round this month. Underwriters are...
22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim CEO...
23:20 , May 25, 2018 |  BC Extra  |  Politics & Policy

China rare disease list could promote R&D, regulatory filings

Five Chinese government agencies, including the State Drug Administration and the National Health Commission, published a national list of 121 qualified rare diseases to support diagnosis and treatment of such conditions in a move that...